IMU
IMUGENE LIMITED ORDINARYImugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
IMU
IMU
IMUGENE LIMITED ORDINARY
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 0.54% | — |
| 10 July | 1.52% | — |
| 9 July | 1.17% | — |
| 8 July | 0.30% | — |
| 7 July | 0.63% | — |
| 6 July | 0.69% | — |
| 3 July | 0.69% | — |
| 2 July | 0.69% | — |
| 1 July | 0.70% | — |
Imugene Limited (IMU) Short Interest Summary
Imugene Limited (IMU) currently has 0.54% of its shares sold short (2.2 million shares, worth approximately $213K), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes IMU the #307 most shorted stock on the ASX most shorted list. Short interest in IMU is down 0.15% over the past week and down 1.23% over the past month. IMU is part of the Health Care sector on the ASX.
Recent IMU Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 0.54% | 2.2M | $0.10 |
| 10 July 2026 | 1.52% | 6.3M | $0.10 |
| 9 July 2026 | 1.17% | 4.9M | $0.10 |
| 8 July 2026 | 0.30% | 1.2M | $0.10 |
| 7 July 2026 | 0.63% | 2.6M | $0.10 |
| 6 July 2026 | 0.69% | 2.9M | $0.14 |
| 3 July 2026 | 0.69% | 2.9M | $0.14 |
| 2 July 2026 | 0.69% | 2.9M | $0.14 |
| 1 July 2026 | 0.70% | 2.9M | $0.14 |
| 30 June 2026 | 0.89% | 3.7M | $0.12 |
IMU Short Selling — Frequently Asked Questions
What is Imugene Limited (IMU)'s current short interest?
Imugene Limited (IMU) currently has a short interest of 0.54% of total shares outstanding. This means 0.54% of IMU's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is IMU heavily shorted on the ASX?
IMU has a relatively low short interest of 0.54%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for IMU investors?
Short interest in IMU shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.54%, IMU's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this IMU short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for IMU.